image:
The image above describes the changes in the mean scores for the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) for ALS patients treated with CL2020. The arrowheads indicate the intravenous administration of CL2020 across six months. It was found that the change in ALSFRS-R scores trended upward over 12 months post-CL2020 treatment compared with 3 months pre-administration. This indicates that repeated CL2020 therapy is safe for ALS patients and has some positive therapeutic effect on certain ALS symptoms.
Credit: Toru Yamashita from Okayama University Graduate School of Medicine
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of motor functions, which eventually leads to death within 5 years of its onset. This disease causes weakness and atrophy of limbs and other muscles, which affect mobility speech, eating, and even breathing in patients. Some drugs, including riluzole, edaravone, and sodium phenylbutyrate/taurursodiol are used for treating ALS, but with limited therapeutic benefits. Therefore, novel, effective ALS treatments are the need of the hour.
Multilineage-differentiating stress-enduring (Muse) cells are pluripotent stem cells derived from the bone marrow, which can be intravenously administered into damaged tissues. Recent studies have found that regular administration of Muse cells causes tissue repair and functional recovery in mouse models of hepatitis, muscle degeneration, and heart attack. Moreover, it leads to significant improvement in limb muscle weakness, inhibits the activation of inflammation and regulates immune functions. Keeping this in view, a Muse cell-based product called CL2020 was developed to utilize the therapeutic potential of Muse cells for treating ALS patients.
Recently, scientists in Japan conducted a single-center open phase II clinical trial to evaluate the safety and treatment efficacy of repeated intravenous injections of CL2020 in patients with ALS. The results of this study were published online in Cell Transplantation on November 28, 2023. The trial was led by Associate Professor Toru Yamashita from Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Dr. Koji Abe from National Center of Neurology and Psychiatry, Japan. Since ALS is a progressive disease, we used multiple regular doses of CL2020, with one monthly dose administered intravenously for six doses. The dosage was set at 15106 cells/dose, proven safe in trials for other illnesses. We only recruited five ALS patients, as this is the first clinical trial for confirming the safety of multiple CL2020 doses, explains Dr. Yamashita.
The primary focus of the trial team was determining the safety and tolerability of CL2020 for up to 12 months after the first administration. In addition, the team assessed disease progression by evaluating the rate of change in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scores over 12 months. ALSFRS-R uses different criteria, including speaking, eating, swallowing, motor functions, and respiratory failure, among others to reflect ALS progression in patients. The team also analyzed the levels of serum tumor necrosis factor- (TNF-), interleukin-6 (IL-6), and sphingosine-1-phosphate (S1P), along with cerebrospinal fluid chitotriosidase-1 (CHIT-1) and neurofilament light chain (NfL), at the beginning of the trial and regularly for 12 months after the first dose. TNF-, IL-6, and S1P are biomarkers associated with inflammatory response and pathogenesis of ALS. Whereas CHIT-1 and NfL are associated with ALS progression and patient survival, which can indicate treatment prognosis and efficacy.
The trial found CL2020 to be highly tolerated by all patients without severe side effects, like pulmonary embolism and anaphylactic shock. However, one patient had a bone fracture a year after the initial dose but with no significant causal relationship to the CL2020 treatment. Furthermore, the rate of change in the ALSFRS-R scores improved at 12 months post-treatment, as compared to at 3 months pre-treatment, and the scores did not worsen until 6 months post-treatment for three patients. This indicates that multiple CL2020 doses can prevent or delay the symptoms of ALS from worsening.
However, the serum IL-6, TNF-, CHIT-1, and NfL levels increased over 6 months post-treatment, suggesting that CL2020 may not suppress the secretion of inflammatory cytokines in ALS patients which only tends to increase with disease progression. In contrast, serum S1P levels continuously decreased over 12 months, indicating that CL2020 might functionally neutralize S1P and thus reduce related signaling in ALS patients.
These findings show that multiple CL2020 doses are safe for use in ALS patients. But while this treatment can potentially abate the worsening of some ALS symptoms, it alone may be inadequate to completely halt disease progression. Therefore, a combination therapy of CL2020 with other drugs currently used for ALS should be considered for future treatments. Given the promising results of this trial, we now need a double-blind study to be conducted, which includes a larger number of ALS patients with a longer observation period to confirm CL2020s efficacy. Thereafter, we can propose this treatment for ALS patients, concludes Dr. Yamashita.
About Okayama University, Japan As one of the leading universities in Japan, Okayama University aims to create and establish a new paradigm for the sustainable development of the world. Okayama University offers a wide range of academic fields, which become the basis of the integrated graduate schools. This not only allows us to conduct the most advanced and up-to-date research, but also provides an enriching educational experience. Website: https://www.okayama-u.ac.jp/index_e.html
About Associate Professor Toru Yamashita from Okayama University, Japan Toru Yamashita is an Associate Professor at the Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan. His areas of research include ischemic stroke, Alzheimers disease, stem cells, and amyotrophic lateral sclerosis, among others. Before he started teaching at Okayama University Prof. Yamashita was a physician and resident at the university hospital and a resident at the National Hospital Organization Okayama Medical Center. He has also been a research fellow at the Department of Physiology at Keio Universitys School of Medicine, Japan and a postdoctoral scientist at Columbia University, USA. In 2010, he won the Japan Stroke Society Young Scholars Award, Okayama Medical Association Award.
Cell Transplantation
Randomized controlled/clinical trial
People
Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial
28-Nov-2023
Toru Yamashita and Koji Abe have patents for the therapeutic use of CL2020 for ALS
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
Originally posted here:
Insights from a phase II clinical trial with CL2020 Muse cell-based therapeutic for Amyotrophic lateral sclerosis - EurekAlert
- Jake Diekman throws BP session for Rangers | MLB.com - MLB.com - August 6th, 2017 [August 6th, 2017]
- Cerebral palsy: Symptoms, diagnosis, treatment - December 5th, 2017 [December 5th, 2017]
- Hypothalamus - the body's thermostat | ASU - Ask A Biologist - December 6th, 2017 [December 6th, 2017]
- When Stroke Affects the Thalamus - Stroke Connection ... - December 28th, 2017 [December 28th, 2017]
- The Endocrine System: Hypothalamus and Pituitary - December 28th, 2017 [December 28th, 2017]
- Hypothalamus - Anatomy, Blood supply and Function | Kenhub - December 28th, 2017 [December 28th, 2017]
- Ulcerative Colitis - Cedars-Sinai - January 6th, 2018 [January 6th, 2018]
- Ulcerative colitis - Treatment - NHS.UK - January 7th, 2018 [January 7th, 2018]
- Business Directory | Uptown Waterloo Business Improvement Area - January 8th, 2018 [January 8th, 2018]
- Will States Continue To Fund Stem Cell Research? : Shots ... - January 28th, 2018 [January 28th, 2018]
- Spinal Cord Injuries - emedicine.medscape.com - February 15th, 2018 [February 15th, 2018]
- Spinal Cord Injuries - spine.org - February 15th, 2018 [February 15th, 2018]
- Journal of Clinical & Experimental Cardiology - Open Access Journals - April 10th, 2018 [April 10th, 2018]
- Cardiology Treatment - Fortis Healthcare - April 10th, 2018 [April 10th, 2018]
- Biology Junction - April 12th, 2018 [April 12th, 2018]
- Managing Right Ventricular Failure in PAH: An Algorithmic ... - April 14th, 2018 [April 14th, 2018]
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in ... - April 22nd, 2018 [April 22nd, 2018]
- Cardiovascular Pharmacotherapeutics: William H. Frishman ... - May 13th, 2018 [May 13th, 2018]
- 13 Super Foods Good for Eczema - Top Eczema Treatments - May 15th, 2018 [May 15th, 2018]
- Diagnosis & Treatment of Parkinson's - ParkinsonsDisease.net - May 30th, 2018 [May 30th, 2018]
- Arizona Heart Rhythm Center - June 10th, 2018 [June 10th, 2018]
- Ayurvedic Medicines for Ulcerative Colitis | Natural ... - June 21st, 2018 [June 21st, 2018]
- Weinstein Cardiovascular Development and Regeneration Meeting - June 30th, 2018 [June 30th, 2018]
- Ulcerative Colitis Information Centre - July 31st, 2018 [July 31st, 2018]
- Sudden Death in Dogs - Pet Health Network | Pet Health ... - August 7th, 2018 [August 7th, 2018]
- Coronary Heart Disease - Ischaemic heart disease - British ... - August 21st, 2018 [August 21st, 2018]
- Cardiac Rehabilitation: Overview, History and Definition ... - August 25th, 2018 [August 25th, 2018]
- Difference between Cardiac Arrest and Respiratory Arrest ... - August 25th, 2018 [August 25th, 2018]
- ECM for Pericardial Closure - Aziyo - August 25th, 2018 [August 25th, 2018]
- Adult Mental Health | Georgia Department of Behavioral Health ... - September 6th, 2018 [September 6th, 2018]
- Mental Health | ECLKC - September 6th, 2018 [September 6th, 2018]
- Mental Health - The Church of Jesus Christ of Latter-day Saints - September 6th, 2018 [September 6th, 2018]
- Center for Vascular Biology - Home | UConn Health - September 22nd, 2018 [September 22nd, 2018]
- # Diabetes Stem Cell Research Diabetes Care Measures - September 30th, 2018 [September 30th, 2018]
- Cardiac Rhythm Disturbances | The Patient Guide to Heart ... - November 2nd, 2018 [November 2nd, 2018]
- Arrhythmia | Cleveland Clinic - November 2nd, 2018 [November 2nd, 2018]
- Hyperbaric Oxygen Therapy for Wound Healing | Johns ... - November 13th, 2018 [November 13th, 2018]
- NIMH Home - November 24th, 2018 [November 24th, 2018]
- What is an interventional cardiologist? | Heart Surgeries ... - November 26th, 2018 [November 26th, 2018]
- Molecular Cardiology Research Institute Boston | Tufts ... - November 29th, 2018 [November 29th, 2018]
- Lower vascular plant | botany | Britannica.com - December 7th, 2018 [December 7th, 2018]
- Welcome to the ABG Tutorial Welcome to Hansen - December 12th, 2018 [December 12th, 2018]
- Cardiac catheterization - Wikipedia - December 12th, 2018 [December 12th, 2018]
- Stem Cell Research & Therapy | Home page - December 22nd, 2018 [December 22nd, 2018]
- Journal of Stem Cell Research and Therapy- Open Access ... - December 22nd, 2018 [December 22nd, 2018]
- Stem-cell therapy - Wikipedia - December 22nd, 2018 [December 22nd, 2018]
- Cardiology and Interventional Cardiology - December 23rd, 2018 [December 23rd, 2018]
- Rhode Island Interventional Cardiology | Cardiovascular ... - December 23rd, 2018 [December 23rd, 2018]
- Interventional Cardiology Certification Policies | ABIM.org - December 23rd, 2018 [December 23rd, 2018]
- Interventional Cardiology - Boston Scientific - December 23rd, 2018 [December 23rd, 2018]
- 9 Benefits of Human Growth Hormone (Along with Side ... - December 27th, 2018 [December 27th, 2018]
- Growth hormone deficiency - Wikipedia - December 27th, 2018 [December 27th, 2018]
- Dr. Lorrie Kirshenbaum, Cardiac Gene Biology | St ... - January 28th, 2019 [January 28th, 2019]
- Cardiomyopathy - CardioSmart - February 8th, 2019 [February 8th, 2019]
- Centenary Institute | Medical Research, Life Saving Research - February 24th, 2019 [February 24th, 2019]
- Cardiovascular Medicine | Department of Medicine - March 29th, 2019 [March 29th, 2019]
- Rapid Test Market 2019 with Recent Trends, Revenue, Demand and Top Manufactures- Bureau Veritas, SGS SA, Intertek Group plc, Eurofins Scientific -... - October 11th, 2019 [October 11th, 2019]
- Medical Imaging Equipment Market Research Report 2019: Global Industry Analysis, Business Development, Size, Share, Trends, Future Growth, Forecast To... - October 11th, 2019 [October 11th, 2019]
- Analysis on the Global DNA Read, Write & Edit Market, 2017-2019 and Forecast to 2024 - Yahoo Finance - October 11th, 2019 [October 11th, 2019]
- Cardiac Surgery Instruments Market is Expected to Tread a Steady Growth Trajectory by Clocking a CAGR of 5.9% from 2017 to 2022 - Health News Office - October 24th, 2019 [October 24th, 2019]
- PEDIATRIC MEDICAL DEVICES MARKET IS PROJECTED TO EXPAND AT A CAGR OF 8.0% FROM 2018 TO 2026 - Health News Office - November 1st, 2019 [November 1st, 2019]
- myTAIHEART Test Provides Evidence for Injury from Biopsy of Heart Transplant Recipients Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Mental health and your heart - British Heart Foundation - November 19th, 2019 [November 19th, 2019]
- BUZZ-U.S. STOCKS ON THE MOVE-Cango, Gulfport Energy, Abiomed, Standard Diversified, Wanda Sports, Eidos - Nasdaq - November 19th, 2019 [November 19th, 2019]
- Cost Analysis of COPD Exacerbations and Cardiovascular Events in SUMMIT - AJMC.com Managed Markets Network - November 19th, 2019 [November 19th, 2019]
- Hundreds walk to defeat ALS in Ancient City - St. Augustine Record - November 22nd, 2019 [November 22nd, 2019]
- Living with Lung Cancer: The Silver Linings - Curetoday.com - November 22nd, 2019 [November 22nd, 2019]
- Building the human spinal cord atlas - SynBioBeta - November 22nd, 2019 [November 22nd, 2019]
- The Week That Wasn't: Keto and the Flu, Human Cyborg, Duvet Disease - Medscape - November 22nd, 2019 [November 22nd, 2019]
- ALS advance offers hope for those diagnosed with deadly disease - WRAL.com - November 22nd, 2019 [November 22nd, 2019]
- ALS Stem Cell Therapy Developer Seeks Amendment to its AstroRx Trial - ALS News Today - November 22nd, 2019 [November 22nd, 2019]
- Former Boston Globe writer, current NHL executive Snow diagnosed with ALS | College Hockey - USCHO - December 23rd, 2019 [December 23rd, 2019]
- AB Science announces the publication of new results in the peer-reviewed journal Glia that further support masitinib's potential mode of action in ALS... - December 23rd, 2019 [December 23rd, 2019]
- Christmas in the City thrills homeless families, takes on poignancy with founders ALS diagnosis - The Boston Globe - December 23rd, 2019 [December 23rd, 2019]
- Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial - Business... - December 23rd, 2019 [December 23rd, 2019]
- RADICAVA (edaravone) - December 23rd, 2019 [December 23rd, 2019]
- List of Amyotrophic Lateral Sclerosis Medications (5 Compared ... - December 23rd, 2019 [December 23rd, 2019]
- Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson's Disease and... - January 14th, 2020 [January 14th, 2020]
- Comprehensive Analysis on Prostacyclin Market based on types and application - Technology Magazine - January 18th, 2020 [January 18th, 2020]
- N.J. karate legend who inspired thousands loses battle with ALS - NJ.com - January 18th, 2020 [January 18th, 2020]